Inhibitors of programmed death receptor 1 (PD-1) and its ligand programmed death‐ligand 1 (PD-L1) are effective in the treatment of advanced squamous and nonsquamous NSCLC (7–11). Here, PDCD1 is linked to non-small cell lung carcinoma.